Lamotrigine induced DRESS syndrome in a child: a case report and literature review

Chien-Heng Lin
China Medical University Hospital

Sheng-Shing Lin
China Medical University Hospital

Syuan-Yu Hong
China Medical University Hospital

Chieh-Ho Chen
China Medical University Hospital

I-Ching Chou (✉ sub179490@gmail.com)
China medical University Children's Hospital

Case report

Keywords: DRESS, lamotrigine

DOI: https://doi.org/10.21203/rs.3.rs-151612/v1

License: ☑️ This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background

Lamotrigine is an important anticonvulsant drug. Its use, however, has been limited by the risk of potentially life-threatening dermatological reactions, such as drug reaction with eosinophilia and systemic symptoms (DRESS).

Case presentation

Here, we report the case of a 7-year-6-month-old girl with a history of epilepsy who developed a skin rash with dyspnoea after 2 weeks of lamotrigine treatment, with DRESS ultimately being diagnosed. After discontinuation of the offending drug and the initiation of systemic glucocorticosteroids, the DRESS symptoms were relieved and the patient was discharged in stable condition.

Conclusion

Anticonvulsant drugs such as lamotrigine among the factors that induce DRESS in children. When a patient displays skin rash and systemic organ involvement following the initiation of an anticonvulsant drug, DRESS should not be overlooked as a diagnosis, and immunosuppressant drugs should be considered as an option for treating DRESS patients.

Background

Anticonvulsant drugs can cause adverse cutaneous reactions, such as drug-induced hypersensitivity syndrome (DIHS), which is characterized by a skin rash, elevated temperature, and the involvement of internal organs, mainly the liver, kidneys, and lungs. The symptoms of DIHS usually develop 2–6 weeks after starting the offending drug but may occur at any time.

Bocquet et al. extended the definition of DIHS and introduced the term DRESS (drug reaction with eosinophilia and systemic symptoms). The drugs most commonly responsible for inducing DRESS include anticonvulsant drugs (carbamazepine, phenobarbital, phenytoin, and lamotrigine), antibiotics (minocycline, ß-lactams, and sulfonamides), antiviral agents, dapsone, sulfasalazine, and allopurinol. The incidence of DRESS has been estimated to be between 1/1000 and 1/1000 exposures to anticonvulsant drugs.

Furthermore, DRESS has previously been reported to be associated with herpesviruses, although existing explanations of how viral infections contribute to the pathogenesis of DRESS remain speculative.

There are two sets of diagnostic criteria for the diagnosis of DRESS; one set consists of the RegiSCAR criteria (Table 1) and the other consists of the SCAR-J criteria developed by Japanese investigators (Table 2). The treatment for DRESS consists of immediate withdrawal of the culprit drug followed by the initiation of systemic steroids.
Table 1
The RegiSCAR diagnostic criteria for DRESS.\textsuperscript{7,8}

|   | Acute rash |
|---|------------|
| 2 | Reaction suspected to be drug-related |
| 3 | Hospitalization |
| 4 | Fever > 38°C |
| 5 | Laboratory abnormalities (at least 1 present) |
| a. | Lymphocytes above or below normal |
| b. | Low platelets |
| c. | Eosinophilia |
| 6 | Involvement of > 1 internal organ |
| 7 | Enlarged lymph nodes > 2 sites |

The first 3 criteria are necessary for diagnosis, along with the presence of 3 out of the other 4.

Table 2
Diagnostic criteria for DiHS established by a Japanese consensus group.\textsuperscript{9}

|   | Maculopapular rash developing > 3 weeks after starting with a limited number of drugs |
|---|----------------------------------------------------------------------------------|
| 2 | Prolonged clinical symptoms after discontinuation of the causative drug |
| 3 | Fever > 38°C |
| 4 | Liver abnormalities (ALT > 100U/L) |
| 5 | Leukocyte abnormalities (at least one present) |
| a. | Leucocytosis (> 11x10^9/L) |
| b. | Atypical lymphocytosis (> 5%) |
| c. | Eosinophilia (> 1.5x10^9/L) |
| 6 | Lymphadenopathy |
| 7 | HHV-6 reactivation |

Case Presentation

A 7-year-6-month-old girl was brought to our emergency room (ER) after experiencing a fever and dyspnoea for 3 days. In the ER, a physical examination revealed lymphadenopathy, mild injected throat with coarse breathing sound, and a maculopapular skin rash on her face, trunk, and limbs (Fig. 1). There were no specific findings upon neurological examination.
Lab data for the patient showed leucocytosis (white blood cell count: 18100/uL) with an elevated level of eosinophils (10%, 1810/uL), with 49.4% neutrophils, 29.2% lymphocytes, and 11% monocytes. The patient's C-reactive protein level was 5.3 mg/dL (normal, < 0.8 mg/dL), while her aspartate transaminase (AST) level and alanine aminotransferase (ALT) level were 253U/L and 93U/L, respectively. A mycoplasma rapid test was positive, and a chest X-ray showed bilateral perihilar lung bronchitis infiltrates. Therefore, bronchopneumonia was suspected initially.

After admission, the patient suffered from progressive dyspnoea, and then was transferred to the paediatric intensive care unit for non-invasive ventilator support with bilevel positive airway pressure support.

In tracing back her past history, it was discovered that she had a history of epilepsy and that was kept under control with an anticonvulsant drug (Depakine, at an initial dose of 250mg qhs). However, her electroencephalography (EEG) results showed generalized epileptiform discharge, and the dose of Depakine was increased to q12h one year ago, at which time her seizures went into remission. However, her body weight changed from 35kg to 42.5kg, resulting in here being overweight (body mass index > 24). Therefore, the anticonvulsant drug was changed to lamotrigine 25mg and then 50mg q12h one month prior to her arrival at the ER. She had already experienced a maculopapular skin rash with itchy sensation one week prior to her arrival in the ER, but it was left untreated.

Because of her clinical presentation of an erythematous rash spread all over her body about 2 weeks after starting lamotrigine, lamotrigine-induced drug reaction with eosinophilia and systemic symptoms (DRESS) was suspected, and pulse therapy with high-dose intravenous methylprednisolone (30mg/day) was prescribed for 3 days and then 1 mg/kg/day. In addition, the anticonvulsant drug was changed to levetiracetam 50mg bid.

Her respiratory condition subsequently improved, and she was then transferred back to a regular ward. However, on her 8th day of hospitalization, her eye became icteric, and her direct/total bilirubin increased to 1.8mg/dL/2.8 mg/dL, before increasing even further to 20.4mg/dL/31.6 mg/dL. Furthermore, her ALT/AST levels increased to 249U/L/225U/L. Meanwhile, an abdominal echo showed mild hepatomegaly. Pulse therapy was then prescribed again, and the patient was also treated with ursodeoxycholic acid and silymarin. She was discharged from the hospital day on the 26th day after her arrival with prescriptions of mycophenolate 2# (180mg/tab) q12h, tacolimus 1# (1mg/cap), and prednisolone 2# (5mg/tab) bid to be taken orally.

**Discussion And Conclusions**

DRESS syndrome is an acute, severe, and life-threatening disease with a mortality rate of about 10%. It is more common in adults and only rarely seen in children, in whom it is frequently associated with systemic organ involvement, such as liver dysfunction, renal impairment, and interstitial pneumonitis. Myocarditis,
thyroiditis, encephalitis, and type 1 diabetes mellitus have also been reported as manifestations of this syndrome.

DRESS usually starts abruptly with maculopapular morbilliform exanthema with fever of > 38°C as of 2–3 weeks after the introduction of the culprit drug. Sometimes, there may be an upper-airway infection-like prodrome, suggesting viral infections as a possible trigger for this syndrome.

A diagnosis of DRESS can be made based on the diagnostic criteria established by the RegiSCAR group (Table 1) or those established by the Japanese Research Committee on Severe Cutaneous Adverse Reaction (Table 2), respectively. Leucocytosis with atypical lymphocytes and eosinophilia of various degrees are unique features of the early phase of DRESS, although leukocytopenia can occasionally precede leucocytosis. Our patient presented with fever and skin rash, and her lab data showed leucocytosis; therefore, mycoplasma pneumonia was suspected initially. However, in tracing back our patient's past history, it was found that she had a history of epilepsy that been controlled initially under treatment with the anticonvulsant drug sodium valproate, which had subsequently been replaced with lamotrigine, 2 weeks after the initiation of which her skin rash first appeared. This drug history was a very important clue for the diagnosis of DRESS.

According to a review article by Shiohara et al., lamotrigine is the fourth most common culprit among anticonvulsant drugs in terms of inducing DRESS. In another study, Brandon et al. reported that among 32 children diagnosed with anticonvulsant hypersensitivity syndrome, 12 of them (37.5%) were taking carbamazepine, 11 of them (34.5%) were taking phenytoin, 5 of them (6.25%) were taking phenobarbital, and 5 of them (6.25%) were taking lamotrigine. In still another study, Wang et al. reported that of 57 patients with DRESS induced by lamotrigine, 14 of them (24.6%) were children. This study found a greater predominance of women with lamotrigine-induced DRESS, but in children, we found a greater predominance of lamotrigine-induced DRESS among boys (with a boy-to-girl ratio = 9:7), and we have summarized the characteristics of 16 published cases of paediatric patients with lamotrigine-induced DIHS/DRESS in Table 3. Four of them had DRESS when lamotrigine was given concurrently with sodium valproate.
Table 3
Characteristics of children (<18 year-old) with lamotrigine-induced DIHS/DRESS in published case studies.\textsuperscript{10–12}

| Case | Age/Sex | Initial dose (mg/day) | Final dose (mg/day) | Latency time (days) | Concurrent drugs | Treatment | Outcome |
|------|---------|----------------------|---------------------|--------------------|------------------|-----------|---------|
| 1    | 11/F    | NA                   | NA                  | NA                 | NA               | Steroid + IVIG | Cured   |
| 2    | 6/M     | NA                   | NA                  | 10                 | VPA              | No steroid | Cured   |
| 3    | 14/M    | NA                   | NA                  | 52                 | NA               | No steroid | Cured   |
| 4    | 8/M     | NA                   | NA                  | 21                 | None             | Steroid   | NA      |
| 5    | 16/F    | NA                   | NA                  | within 56          | NA               | NA        | NA      |
| 6    | 17/F    | 50                   | 50                  | 21                 | None             | Steroid   | Cured   |
| 7    | 4/F     | NA                   | NA                  | NA                 | NA               | NA        | NA      |
| 8    | 2/F     | NA                   | NA                  | NA                 | NA               | NA        | NA      |
| 9    | 3/M     | NA                   | NA                  | NA                 | NA               | NA        | NA      |
| 10   | 7/M     | NA                   | NA                  | NA                 | NA               | NA        | NA      |
| 11   | 12/M    | NA                   | NA                  | NA                 | NA               | NA        | NA      |
| 12   | 6/M     | NA                   | NA                  | NA                 | VPA              | No steroid | Cured   |
| 13   | 15/F    | 50                   | 75                  | 30                 | VPA 2000mg/d     | NA        | NA      |
| 14   | 12/M    | 25                   | 50                  | 18                 | VPA              | Steroid   | Cured   |
| 15   | 4/M     | NA                   | NA                  | 30                 | NA               | IVIG + plasma exchange | Cured |
| 16   | 7/F     | 50                   | 100                 | 14                 | NA               | Steroid + mycophenolate + tacolimus | Cured |

VPA = valproic acid, IVIG = intravenous immunoglobulin, NA = not available

About 50–60% of cases of DRESS with organ involvement occur in the liver, and such DRESS may progress into fulminant hepatitis or hepatomegaly, with hepatic failure being a common cause of death.\textsuperscript{11}

Systemic corticosteroids have been accepted as the gold standard treatment for ameliorating the clinical symptoms of DRESS. However, they need to be tapered over 6–8 weeks to prevent the relapse of various symptoms.\textsuperscript{3} The usage of intravenous immunoglobulin (IVIG) for patients with life-threatening signs such as renal failure or respiratory failure has also been recommended.\textsuperscript{10–13} Meanwhile, some authors have reported beneficial effects of the concomitant use of N-acetyl cysteine because of its detoxifying
capabilities. Alexander et al. reported a dramatic, sustained clinical response to therapeutic plasma exchange after a steroid treatment failed in a paediatric case of DRESS associated with either lamotrigine or bupropion, leading to multiorgan involvement and life-threatening complications of respiratory failure and cardiac arrest. Our patient presented fever and dyspnoea initially, and her symptoms progressed to pulmonary insufficiency requiring non-invasive positive pressure ventilator support. Furthermore, our patient developed jaundice with severe liver dysfunction, and the immunosuppressant drugs of mycophenolate and tacrolimus were even prescribed after steroid therapy due to hepatic failure. The use of immunosuppressant drugs for DRESS has never previously been reported in the literature. Our patient may thus be the first patient with a case of DRESS treated with immunosuppressant drugs.

The pathogenesis of DRESS remains a matter of speculation, but several theories have been proposed. One theory is that the anticonvulsants are converted into toxic arene oxide metabolites, which are then metabolized by enzymes within the body. Another neoantigen theory speculates that toxic arene oxide reactive metabolites may also alter the cytochrome P450 enzymes, such as those in the liver, skin, kidneys, stomach, intestinal tract, and lungs. In short, it is generally regarded, like other severe drug eruptions, as a T-cell mediated hypersensitivity reaction. Therefore, the clinical resolution of DRESS is associated with a shift away from Tregs to Th 17 cell differentiation.

DRESS should be considered in patients with skin rash and liver function impairment occurring several weeks after the initiation of an anticonvulsant drug. Relatedly, the early recognition and early withdrawal of allergenic drugs is a very important aspect of the management of DRESS. Glucocorticoid therapy is the first choice treatment, and plasma exchange, IVIG, and immunosuppressant drugs should be considered for multiorgan involvement and life-threatening complications.

**Abbreviations**

ALT
Alanine aminotransferase
AST
Aspartate transaminase
DIHS
Drug-induced hypersensitivity syndrome
DRESS
Drug reaction with eosinophilia and systemic symptoms
EEG
Electroencephalography
ER
Emergency room
IVIG
Intravenous immunoglobulin
Declarations

Ethics approval and consent to participate: The institutional review board of China Medical University approved this study and the patient's family gave their written informed consent.

Consent for publication: All of the authors and the patient's family members have consented to the publication of this research.

Availability of data and materials: The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests: The authors declare that they have no competing interests

Funding: No funding was received for this research.

Authors' contributions: CHL contributed to the conception and design of the study, the acquisition and validation of data, and the drafting and revision the manuscript. ICC supervised the study process and was involved in the conception and design of the study. SSL played a prominent role in data validation. SYH assisted in data acquisition, analysis, and manuscript revision. CCH interpreted the data, drafted and revised the manuscript. All authors read and approved the final manuscript.

Acknowledgements: The authors would like to thank the patient's family members for their assistance throughout the study period.

References

1. Bocquet H, Bagot M, Roujeau JC. Drug induced pseudolymphoma and drug hypersensitivity syndrome (drug rush with eosinophilia and systemic symptoms-DRESS). Semin Cutan Med Surg 1996;15:250-7.
2. Saida S, Yoshida A, Tanaka R, Abe J, Hamahata K, Okumura M, Momoi T. A case of drug-induced hypersensitivity syndrome-like symptoms following HHV-6 encephalopathy. Allergol Int. 2015;59:83-6.
3. Shiohara T, Mizukawa Y. Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): An update in 2019. Allergol Int. 2019;68(3):301-8.
4. Knowles SR, Shapiro L, Shear NH. Anticonvulsant hypersensitivity syndrome: Incidence prevention and management. Drug Saf. 1999;21:489-501.
5. Hagiya H, Iwamuro M, Tanaka T, Hasegawa K, Hanayama Y, Kimura M, Otsuka F. Reactivation of human herpes virus-6 in the renal tissue of a patient with drug-induced hypersensitivity syndrome/drug rash with eosinophilia and systemic symptoms (DiHS/DRESS). Intern Med. 2016;55(13):1769-74.
6. Kardaun SH, Sidoroff A, Valeyrle-Allanore L, Halevy S, Davidovici BB, Mockenhaupt M, Roujeau JC. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol. 2007;156(3):609-11.
7. Hung S-I, Chung W-H, Liou L-B, Chu C-C, Lin M, Huang H-P, Lin Y-L, Lan J-L, Yang L-C, Hong H-S, Chen M-J, Lai P-C, Wu M-S, Chu C-Y, Wang K-H, Chen C-H, Fann CSJ, Wu J-Y, Chen Y-T. HLA-B*5801 alleles as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA. 2005;102(11):4134-9.

8. Mizukawa Y, Hirahara K, Kano Y, Shiohara T. Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS) severity score: a useful tool for assessing disease severity and predicting fatal cytomegalovirus disease. J Am Acad Dermatol. 2019;80:670e8.

9. Newell BD, Moinfar M, Mancini AJ, Nopper AJ. Retrospective analysis of 32 pediatric patients with anticonvulsant hypersensitivity syndrome (ACHSS). Pediatr Dermatol. 2009;26(5):536-46.

10. Wang X-Q, Lv B, Wang H-F, Zhang X, Yu S-Y, Huang X-S, Zhang J-T, Tian C-L, Lang S-Y. Lamotrigine induced DIHS/DRESS: Manifestations, treatment, and outcome in 57 patients. Clin Neurol Neurosurg. 2015;138:1-7.

11. Roujeau JC. Treatment of severe drug eruptions. J Dermatol 1999;26:718-22.

12. Moling O, Tappeiner L, Piccin A, Pagani E, Rossi P. Treatment of DIHSDRESS with comined N-acetylcysteine, prednisone and valganciclovir-a hypothesis. Med Sci Moni. 2012;18:57-62.

13. Alexander T, Iglesia E, Park Y, Duncan D, Pedan D, Shiekh S, Ferris M. Severe DRESS syndrome managed with therapeautic plasma exchange. Pediatrics 2013;131:3

14. Spielberg SP, Gordon GE, Blake DA, Mellits ED, Bross DS. Anticonvulsant toxicity in vitro: possible role of arene oxides. J Pharmcol Exper Therapy. 1981;217:386-9.

15. Tas S, Simonart T. Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome): an update. Dermatol 2003;206:353-6.

**Figures**
Figure 1

Scattered red maculopapular rash on the trunk and limbs, partially pressed to fade and partially fused into patches.